Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR phase 3 trial in first-line advanced renal cell carcinoma
jRCT2080223751Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Lenvatinib + everolimus, Lenvatinib + pembrolizumab and Sunitinib (3 arms). Started Dec 2017; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080223751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223751.